JP2005527487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527487A5 JP2005527487A5 JP2003557380A JP2003557380A JP2005527487A5 JP 2005527487 A5 JP2005527487 A5 JP 2005527487A5 JP 2003557380 A JP2003557380 A JP 2003557380A JP 2003557380 A JP2003557380 A JP 2003557380A JP 2005527487 A5 JP2005527487 A5 JP 2005527487A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- cooh
- compound
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 238000002560 therapeutic procedure Methods 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 150000001495 arsenic compounds Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- -1 nitrosurea Chemical compound 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000009527 Refractory anemia Diseases 0.000 claims 4
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003053 toxin Substances 0.000 claims 4
- 231100000765 toxin Toxicity 0.000 claims 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 206010005949 Bone cancer Diseases 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 201000006491 bone marrow cancer Diseases 0.000 claims 3
- 201000007455 central nervous system cancer Diseases 0.000 claims 3
- 229940044683 chemotherapy drug Drugs 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000010453 lymph node cancer Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000002314 small intestine cancer Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 229930192392 Mitomycin Natural products 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 229940123468 Transferase inhibitor Drugs 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 229960001445 alitretinoin Drugs 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229940086322 navelbine Drugs 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims 1
- 108010081690 Pertussis Toxin Proteins 0.000 claims 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 claims 1
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 claims 1
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 0 C*1CCCC1 Chemical compound C*1CCCC1 0.000 description 3
- DELIRPXYVPFZSP-UHFFFAOYSA-N CC(CCC1C)S1=C Chemical compound CC(CCC1C)S1=C DELIRPXYVPFZSP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34649202P | 2002-01-07 | 2002-01-07 | |
| PCT/US2003/000281 WO2003057012A2 (en) | 2002-01-07 | 2003-01-07 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009279362A Division JP5603593B2 (ja) | 2002-01-07 | 2009-12-09 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005527487A JP2005527487A (ja) | 2005-09-15 |
| JP2005527487A5 true JP2005527487A5 (https=) | 2006-08-17 |
| JP4571408B2 JP4571408B2 (ja) | 2010-10-27 |
Family
ID=23359639
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557380A Expired - Lifetime JP4571408B2 (ja) | 2002-01-07 | 2003-01-07 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| JP2009279362A Expired - Fee Related JP5603593B2 (ja) | 2002-01-07 | 2009-12-09 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| JP2013172071A Pending JP2013237701A (ja) | 2002-01-07 | 2013-08-22 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| JP2015051753A Pending JP2015120745A (ja) | 2002-01-07 | 2015-03-16 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009279362A Expired - Fee Related JP5603593B2 (ja) | 2002-01-07 | 2009-12-09 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| JP2013172071A Pending JP2013237701A (ja) | 2002-01-07 | 2013-08-22 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| JP2015051753A Pending JP2015120745A (ja) | 2002-01-07 | 2015-03-16 | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US6911471B2 (https=) |
| EP (3) | EP2462932A1 (https=) |
| JP (4) | JP4571408B2 (https=) |
| AU (1) | AU2003207455B2 (https=) |
| CA (1) | CA2472633C (https=) |
| WO (1) | WO2003057012A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911471B2 (en) * | 2002-01-07 | 2005-06-28 | The Texas A&M University System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| TWI411431B (zh) * | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| AU2011204901B2 (en) * | 2004-07-16 | 2013-09-12 | Board Of Regents, The University Of Texas System | Compounds and methods for treatment of cancer |
| ES2532666T3 (es) * | 2005-07-29 | 2015-03-30 | Solasia Pharma K.K. | Compuestos y métodos para el tratamiento del cáncer |
| WO2007082104A2 (en) * | 2006-01-13 | 2007-07-19 | The Texas A & M University System | Compounds and methods for the treatment of cancer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| JP5301449B2 (ja) * | 2006-11-01 | 2013-09-25 | ニューサウス イノベイションズ ピーティーワイ リミテッド | 有機アルセノキシド化合物およびその使用 |
| KR20100100835A (ko) * | 2007-11-02 | 2010-09-15 | 지오팜 온콜로지 인코포레이티드 | 유기 비소제와의 병용 요법 |
| SG186599A1 (en) * | 2007-12-12 | 2013-01-30 | Ziopharm Oncology Inc | Compounds and methods for the treatment of cancer |
| CN102105793A (zh) * | 2008-05-28 | 2011-06-22 | 巴斯夫欧洲公司 | 评估肝酶诱导的工具和方法 |
| RU2534606C2 (ru) | 2008-08-20 | 2014-11-27 | Зайофарм Онколоджи, Инк. | Мышьякорганические соединения и способы лечения рака |
| AU2011242988B2 (en) * | 2010-04-19 | 2013-02-07 | Sri International | Compositions and method for the treatment of multiple myeloma |
| TWI617305B (zh) * | 2013-12-05 | 2018-03-11 | 蘇愛康制藥有限公司 | 治療癌症的化合物及其應用程序 |
| CN112941027B (zh) * | 2021-03-19 | 2021-11-02 | 苏州大学 | 二甲基亚胂酸致人角质形成细胞恶性转化细胞株及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2349729A (en) * | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| US2701812A (en) * | 1951-06-26 | 1955-02-08 | Dainippon Pharmaceutical Co | Diarylarsenious acid derivatives and the preparation thereof |
| DE3229565A1 (de) * | 1982-08-07 | 1984-02-16 | Etschenberg, Eugen, Dr., 5000 Köln | Arsenhaltige nucleoside |
| FR2640269B1 (fr) * | 1988-12-13 | 1991-03-15 | Maes Ludo | Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant |
| JP2001519366A (ja) * | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| IL136051A0 (en) * | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) * | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| AUPQ296799A0 (en) * | 1999-09-20 | 1999-10-14 | Unisearch Limited | A cell-membrane impermeable trivalent organoarsenical derivative and use thereof |
| EP1328253B1 (en) * | 2000-04-26 | 2006-03-22 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| AUPR379801A0 (en) | 2001-03-19 | 2001-04-12 | Unisearch Limited | Use of a substantially cell membrane impermeable compound for treating arthritis |
| AUPR598901A0 (en) | 2001-06-28 | 2001-07-19 | Unisearch Limited | Inhibition of angiogenesis by targeting protein tyrosine phosphatases |
| ATE446784T1 (de) | 2001-07-06 | 2009-11-15 | Cochlear Ltd | Konfiguration implantierter vorrichtungen |
| US6911471B2 (en) * | 2002-01-07 | 2005-06-28 | The Texas A&M University System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| CA2504935C (en) | 2002-11-07 | 2012-04-10 | Newsouth Innovations Pty Limited | Induction of the mitochondrial permeability transition |
| TWI411431B (zh) | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| JP5301449B2 (ja) | 2006-11-01 | 2013-09-25 | ニューサウス イノベイションズ ピーティーワイ リミテッド | 有機アルセノキシド化合物およびその使用 |
-
2003
- 2003-01-07 US US10/337,969 patent/US6911471B2/en not_active Expired - Lifetime
- 2003-01-07 CA CA2472633A patent/CA2472633C/en not_active Expired - Fee Related
- 2003-01-07 WO PCT/US2003/000281 patent/WO2003057012A2/en not_active Ceased
- 2003-01-07 AU AU2003207455A patent/AU2003207455B2/en not_active Ceased
- 2003-01-07 JP JP2003557380A patent/JP4571408B2/ja not_active Expired - Lifetime
- 2003-01-07 EP EP11187256A patent/EP2462932A1/en not_active Withdrawn
- 2003-01-07 EP EP20110187261 patent/EP2420229A1/en not_active Withdrawn
- 2003-01-07 EP EP03705662.9A patent/EP1474128B1/en not_active Expired - Lifetime
-
2005
- 2005-01-13 US US11/035,178 patent/US6995188B2/en not_active Expired - Lifetime
-
2006
- 2006-02-06 US US11/349,043 patent/US7619000B2/en not_active Expired - Lifetime
-
2007
- 2007-08-20 US US11/894,807 patent/US20080090904A1/en not_active Abandoned
-
2009
- 2009-12-09 JP JP2009279362A patent/JP5603593B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-22 JP JP2013172071A patent/JP2013237701A/ja active Pending
-
2015
- 2015-03-16 JP JP2015051753A patent/JP2015120745A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527487A5 (https=) | ||
| US12048682B2 (en) | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy | |
| CN105452258B (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| JP6315841B2 (ja) | 有機ヒ素化合物および癌を処置するための方法 | |
| JP2018039853A5 (https=) | ||
| JP2009502971A5 (https=) | ||
| JP4994374B2 (ja) | がんを治療するための化合物および方法 | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| McClay et al. | A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma | |
| CN104602710A (zh) | 癌症治疗 | |
| JP6656484B2 (ja) | 放射性抗腫瘍剤 | |
| CN101395166B (zh) | 用于治疗癌症的化合物和方法 | |
| CN101155600B (zh) | 放射线治疗增强剂 | |
| Sancho et al. | The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study | |
| Colina-Vegas et al. | Copper (I)–phosphine complexes: a promising approach in the search for antitumor agents | |
| Sartor et al. | Stromal targeted therapy in bone metastatic prostate cancer: promise delivered | |
| Kohorn | Uracil Mustard and 5-Fluorouracil Combination Chemotherapy: A Historic Record. | |
| JP6494400B2 (ja) | 放射性抗腫瘍剤、及び、抗腫瘍用キット | |
| CN105899486A (zh) | 用于治疗癌症的化合物和方法 | |
| Yunhua et al. | Cisplatin as a radiosensitizer in clinical practice: a pilot study | |
| Dodokhova et al. | Comparative analysis of the pharmacological activity of bis (3, 5-di-tert-butyl-4-hydroxyphenylthiolate) dimethylol in different modes of administration on a mouse model of melanoma B16 tumor growth | |
| US20130018028A1 (en) | Bi-(indole-2-aceto)-iron II (Ferrous Indole Acetate) | |
| US20100111867A1 (en) | Carborane-phosphonium compounds and their use in boron neutron capture therapy and imaging | |
| JPWO2006062072A1 (ja) | 転移癌治療剤および癌転移抑制剤 | |
| HK1228370A1 (en) | Compounds and methods for the treatment of cancer |